Role of systematic lymphadenectomy and adjuvant therapy in stage I uterine papillary serous carcinoma

M. Bijoy Thomas, Andrea Mariani, William Arthur Cliby, Gary Keeney, Karl C. Podratz, Sean Christopher Dowdy

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Objective: To assess surgical staging with systematic lymphadenectomy (LND) and adjuvant therapy in patients with stage I uterine papillary serous carcinoma (UPSC). Methods: A single-institution, retrospective review was conducted of all surgically treated patients with primary UPSC between 1982 and 2005. Results: 42 patients (IA = 15, IB = 21, IC = 6) were stage I. 81% (n = 34) underwent LND (median 40 nodes), 69% omentectomy, and 45% peritoneal biopsies. Median follow-up was 39 months. The 5-year overall survival (OS) and progression free survival (PFS) rates were 85% and 78%. The substage 5-year OS was: IA 100%, IB 89%, IC 60%. No lymphatic recurrences (LR) were observed in 34 patients who had LND compared to 1 LR in 8 who did not undergo LND (p = NS). No recurrences were detected among the 15 patients with stage IA UPSC, irrespective of post-operative therapy. None of the 20 IB and IC patients who received radiation therapy (RT) had vaginal recurrences (VR) compared to 2 of the 7 (29%) who did not receive RT (p = 0.02). A systematic LND (> 20 lymph nodes) was performed in 19 stage IB and IC patients. No hematological or peritoneal recurrence (HPR) was detected in the 6 patients who received chemotherapy. In contrast, HPR were observed in 3 (23%) of 13 patients who did not receive chemotherapy. Discussion: Observation is an option for patients with stage IA UPSC confirmed by systematic LND. Patients with comprehensively staged IB and IC UPSC are candidates for chemotherapy and vaginal brachytherapy to prevent HPR and VR.

Original languageEnglish (US)
Pages (from-to)186-189
Number of pages4
JournalGynecologic Oncology
Volume107
Issue number2
DOIs
StatePublished - Nov 2007

Fingerprint

Papillary Carcinoma
Lymph Node Excision
Recurrence
Lymph Nodes
Therapeutics
Drug Therapy
Radiotherapy
Survival
Brachytherapy
Disease-Free Survival
Survival Rate
Observation
Biopsy

Keywords

  • Stage I
  • Systematic lymphadenectomy
  • Uterine papillary serous cancer

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Role of systematic lymphadenectomy and adjuvant therapy in stage I uterine papillary serous carcinoma. / Thomas, M. Bijoy; Mariani, Andrea; Cliby, William Arthur; Keeney, Gary; Podratz, Karl C.; Dowdy, Sean Christopher.

In: Gynecologic Oncology, Vol. 107, No. 2, 11.2007, p. 186-189.

Research output: Contribution to journalArticle

@article{f8d0a28906144733ae2bd16269b4cfa2,
title = "Role of systematic lymphadenectomy and adjuvant therapy in stage I uterine papillary serous carcinoma",
abstract = "Objective: To assess surgical staging with systematic lymphadenectomy (LND) and adjuvant therapy in patients with stage I uterine papillary serous carcinoma (UPSC). Methods: A single-institution, retrospective review was conducted of all surgically treated patients with primary UPSC between 1982 and 2005. Results: 42 patients (IA = 15, IB = 21, IC = 6) were stage I. 81{\%} (n = 34) underwent LND (median 40 nodes), 69{\%} omentectomy, and 45{\%} peritoneal biopsies. Median follow-up was 39 months. The 5-year overall survival (OS) and progression free survival (PFS) rates were 85{\%} and 78{\%}. The substage 5-year OS was: IA 100{\%}, IB 89{\%}, IC 60{\%}. No lymphatic recurrences (LR) were observed in 34 patients who had LND compared to 1 LR in 8 who did not undergo LND (p = NS). No recurrences were detected among the 15 patients with stage IA UPSC, irrespective of post-operative therapy. None of the 20 IB and IC patients who received radiation therapy (RT) had vaginal recurrences (VR) compared to 2 of the 7 (29{\%}) who did not receive RT (p = 0.02). A systematic LND (> 20 lymph nodes) was performed in 19 stage IB and IC patients. No hematological or peritoneal recurrence (HPR) was detected in the 6 patients who received chemotherapy. In contrast, HPR were observed in 3 (23{\%}) of 13 patients who did not receive chemotherapy. Discussion: Observation is an option for patients with stage IA UPSC confirmed by systematic LND. Patients with comprehensively staged IB and IC UPSC are candidates for chemotherapy and vaginal brachytherapy to prevent HPR and VR.",
keywords = "Stage I, Systematic lymphadenectomy, Uterine papillary serous cancer",
author = "Thomas, {M. Bijoy} and Andrea Mariani and Cliby, {William Arthur} and Gary Keeney and Podratz, {Karl C.} and Dowdy, {Sean Christopher}",
year = "2007",
month = "11",
doi = "10.1016/j.ygyno.2007.05.044",
language = "English (US)",
volume = "107",
pages = "186--189",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Role of systematic lymphadenectomy and adjuvant therapy in stage I uterine papillary serous carcinoma

AU - Thomas, M. Bijoy

AU - Mariani, Andrea

AU - Cliby, William Arthur

AU - Keeney, Gary

AU - Podratz, Karl C.

AU - Dowdy, Sean Christopher

PY - 2007/11

Y1 - 2007/11

N2 - Objective: To assess surgical staging with systematic lymphadenectomy (LND) and adjuvant therapy in patients with stage I uterine papillary serous carcinoma (UPSC). Methods: A single-institution, retrospective review was conducted of all surgically treated patients with primary UPSC between 1982 and 2005. Results: 42 patients (IA = 15, IB = 21, IC = 6) were stage I. 81% (n = 34) underwent LND (median 40 nodes), 69% omentectomy, and 45% peritoneal biopsies. Median follow-up was 39 months. The 5-year overall survival (OS) and progression free survival (PFS) rates were 85% and 78%. The substage 5-year OS was: IA 100%, IB 89%, IC 60%. No lymphatic recurrences (LR) were observed in 34 patients who had LND compared to 1 LR in 8 who did not undergo LND (p = NS). No recurrences were detected among the 15 patients with stage IA UPSC, irrespective of post-operative therapy. None of the 20 IB and IC patients who received radiation therapy (RT) had vaginal recurrences (VR) compared to 2 of the 7 (29%) who did not receive RT (p = 0.02). A systematic LND (> 20 lymph nodes) was performed in 19 stage IB and IC patients. No hematological or peritoneal recurrence (HPR) was detected in the 6 patients who received chemotherapy. In contrast, HPR were observed in 3 (23%) of 13 patients who did not receive chemotherapy. Discussion: Observation is an option for patients with stage IA UPSC confirmed by systematic LND. Patients with comprehensively staged IB and IC UPSC are candidates for chemotherapy and vaginal brachytherapy to prevent HPR and VR.

AB - Objective: To assess surgical staging with systematic lymphadenectomy (LND) and adjuvant therapy in patients with stage I uterine papillary serous carcinoma (UPSC). Methods: A single-institution, retrospective review was conducted of all surgically treated patients with primary UPSC between 1982 and 2005. Results: 42 patients (IA = 15, IB = 21, IC = 6) were stage I. 81% (n = 34) underwent LND (median 40 nodes), 69% omentectomy, and 45% peritoneal biopsies. Median follow-up was 39 months. The 5-year overall survival (OS) and progression free survival (PFS) rates were 85% and 78%. The substage 5-year OS was: IA 100%, IB 89%, IC 60%. No lymphatic recurrences (LR) were observed in 34 patients who had LND compared to 1 LR in 8 who did not undergo LND (p = NS). No recurrences were detected among the 15 patients with stage IA UPSC, irrespective of post-operative therapy. None of the 20 IB and IC patients who received radiation therapy (RT) had vaginal recurrences (VR) compared to 2 of the 7 (29%) who did not receive RT (p = 0.02). A systematic LND (> 20 lymph nodes) was performed in 19 stage IB and IC patients. No hematological or peritoneal recurrence (HPR) was detected in the 6 patients who received chemotherapy. In contrast, HPR were observed in 3 (23%) of 13 patients who did not receive chemotherapy. Discussion: Observation is an option for patients with stage IA UPSC confirmed by systematic LND. Patients with comprehensively staged IB and IC UPSC are candidates for chemotherapy and vaginal brachytherapy to prevent HPR and VR.

KW - Stage I

KW - Systematic lymphadenectomy

KW - Uterine papillary serous cancer

UR - http://www.scopus.com/inward/record.url?scp=35348818965&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35348818965&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2007.05.044

DO - 10.1016/j.ygyno.2007.05.044

M3 - Article

C2 - 17688926

AN - SCOPUS:35348818965

VL - 107

SP - 186

EP - 189

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -